Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSLIW6)

• Drug Name: MIN-117 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Major depressive disorder	6A70.3	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 74424169
  TTD Drug ID: DMSLIW6

Molecule-Related Drug Atlas

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[4]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[5]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[7]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[8]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[9]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[10]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[6]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[6]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[6]

Drug(s) Targeting Dopamine transporter (DAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[9]
Dasotraline	DMLDQFV	Attention deficit hyperactivity disorder	6A05.Z	Approved	[11]
Methylphenidate	DM7SJD6	Attention deficit hyperactivity disorder	6A05.Z	Approved	[12]
Modafinil	DMYILBE	Malignant glioma	2A00.0	Approved	[6]
Phenmetrazine	DMXYTN9	Obesity	5B81	Approved	[13]
Ioflupane i-123	DMNARJT	Parkinson disease	8A00.0	Approved	[14]
DEXMETHYLPHENIDATE HYDROCHLORIDE	DM8WBAH	Attention deficit hyperactivity disorder	6A05.Z	Approved	[15]
Altropane	DMO9WDS	Attention deficit hyperactivity disorder	6A05.Z	Approved	[16]
Amitifadine	DMS1X67	Obesity	5B81	Phase 3	[17]
NAV5001	DMRSI1M	Dementia	6D80-6D86	Phase 3	[16]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[6]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[18]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[19]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[20]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[7]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[21]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[22]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[23]
Treximet	DMU54QB	Migraine	8A80	Approved	[24]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[25]

Drug(s) Targeting 5-HT receptor (5HTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[26]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[14]
Ramosetron	DMH7GN8	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[26]
Pizotyline	DMV74ZH	Headache	8A80-8A84	Approved	[14]
Tandospirone	DMPHWU6	Anxiety disorder	6B00-6B0Z	Approved	[26]
Nafronyl	DMVMQ1L	Cerebrovascular ischaemia	8B1Z	Approved	[14]
ITI-007	DMUQ1DO	Depression	6A70-6A7Z	Phase 3	[3]
Fenfluramine	DM0762O	Dravet syndrome	8A61.11	Phase 3	[27]
Lu-AA34893	DM2ZUXK	Anxiety disorder	6B00-6B0Z	Phase 2	[28]
SEP--4199	DMA12HB	Bipolar disorder	6A60	Phase 2	[29]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Antagonist	[2]
5-HT receptor (5HTR)	TT85JO3	NOUNIPROTAC	Antagonist	[3]
Dopamine transporter (DAT)	TTVBI8W	SC6A3_HUMAN	Inhibitor	[3]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037483)
• [2] Company report (Minerva Neurosciences),MIN-101,Schizophrenia, 6 trials completed; Once a day formulation completed , Phase IIa completed; Phase IIb enrollment ongoing and expected to continue over the last 3 quarters of 2015.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [5] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [8] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [9] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [10] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [11] Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
• [12] Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
• [13] Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [15] Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
• [16] Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
• [18] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [19] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [20] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [21] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [22] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [23] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [24] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [26] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [27] Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
• [28] Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105).
• [29] ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health.